个人简介

徐明  副研究员，北京大学第三医院血管医学所，心内科

---

1996年毕业于北京医科大学医疗系；

1997年获日本文部省奖学金赴日本名古屋大学留学；

2001年于日本名古屋大学获医学博士学位；

2001-2003 北京大学第三医院血管医学研究所博士后；

2007-至今 北京大学第三医院血管医学研究所副研究员，硕士生导师。

    2006年入选北京市科技新星培训计划。2007年获“中国药理学会Servier青年药理学工作者奖”，2008年获北京大学医学部优秀青年学者称号，2009年入选教育部新世纪优秀人才支持计划，北京市优秀人才资助计划，获“中国生理学会张锡钧基金优秀论文二等奖”。

    曾承担国家自然科学基金项目1项， 教育部教育振兴行动计划专项基金(985工程)项目1项， 教育部回国人员启动基金项目1项，北京大学医学部心血管（基础）研究基金项目1项，曾参加了国家自然科学基金重大项目的研究工作。现承担北京市自然科学基金《心肌重塑中STATs的基因转录调控研究》，教育部新世纪优秀人才支持计划，北京市优秀人才培养资助项目《基于天然化学小分子探针的心脏保护机制研究》，参与863项目《重大疾病及常见病诊断技术和临床医学研究课题》的工作。

     现任中国心电学会青年学术委员、中国病理生理学会心血管专业委员会青年委员、国际心脏病研究会（ISHR）中国分会执委会青年委员，中西医结合学会微循环专业委员会委员，中华医学会心血管专业委员会基础和检验学组组员，《中国介入心脏病学杂志》编委。

CURRICULUM VITAE

Ming Xu

 #49. Huayuan Bei Road, Haidian District                                                                                                        

Department of Cardiology

Institute of Vascular Medicine

Peking University Third Hospital

Beijing 100191                                                                                  

Tel:+86-10-82265519

xuminghi@bjmu.edu.cn                                

EDUCATION:

1996, Health Science Center of Peking University, Bachelor Degree of Medicine; 2001, Nagoya University of Japan, Ph.D Degree

PROFESSIONAL EXPERIENCE:

2007-present, Associate Professor, Deparment of Cardiology, Peking University Third Hospital;

2003-2007, Assistant Professor, Deparment of Cardiology, Peking University Third Hospital;

2001-2003, Postdoctoral Training, Institute of Vascular Medicine, Peking University Third Hospital

RESEARCH INTERESTE:

1.        Understanding molecule mechanisms of the transition from the hypertrophy to heart failure.

2.        Exploring the heart protective mechanisms during ischemia-reperfusion.

RESEARCH ACTIVITIES:

2005 Excellent Academic Paper Awarded at the National Pharmacology Conference

2006 Authorized to join Beijing “New Star” Program

2007 SERVIER Prize for Young Investigator of Chinese Pharmacological Society

2008 Excellent Young Scholar of Peking University Health Science Center

2009 Authorized to join the Program for New Century Excellent Talents in University and Beijing Talents Foundation

Now a committee member of Chinese Cardiac Electrophysiology Society, International Society for Heart Research (ISHR) Chinese Section and Cardiovascular Professional Committee of China’s Society of Pathophysiology.

1.  Xuehui Liu, Yingli Gai, Fei Liu, Wei Gao, Youyi Zhang, Ming Xu* and Zhaoping Li*.  Trimetazidine inhibits pressure overload-induced cardiac fibrosis through NADPH oxidase-ROS-CTGF pathway. Cardiovascular Research 2010; doi: 10.1093/cvr/cvq181.

2.  A distinct AMP-activated protein kinase phosphorylation site characterizes cardiac hypertrophy induced by L-thyroxine and angiotensin II. Sheng-Yang Jiang, Ming Xu, Xiao-Wei Ma, Han Xiao and You-Yi Zhang. Clinical and Experimental Pharmacology and Physiology (2010). doi: 10.1111/j.1440-1681.2010.05404.x.

3.  Xu M. Signaling pathways in pressure overload-induced cardiac remodeling: A dynamic entity. Clin Exp Pharmacol Physiol. 2010, 37:10–11.

4.    Ai D, Pang W, Li N, Xu M, Jones PD, Yang J, Zhang Y, Chiamvimonvat N, Shyy JY, Hammock BD, Zhu Y. Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy. Proc Natl Acad Sci U S A. 2009, 106:564-569.

5.   Gong K, Li Z, Xu M, Du J, Lv Z, Zhang Y. A novel protein kinase A-independent, beta-arrestin-1-dependent signaling pathway for p38 mitogen-activated protein kinase activation by beta2-adrenergic receptors. J Biol Chem. 2008, 283:29028-29036.

6.   Xu M, Zhou P, Xu SM, Liu Y, Feng X, Bai SH, Bai Y, Hao XM, Han Q, Zhang Y, Wang SQ. Intermolecular Failure of L-type Ca(2+) Channel and Ryanodine Receptor Signaling in Hypertrophy. PLoS Biol. 2007,  5:203-211.